Europe Alpha 1 Antitrypsin Deficiency Aatd Augmentation Therapy Market Analysis

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Europe Alpha 1 Antitrypsin Deficiency Aatd Augmentation Therapy Market Analysis

  • Pharmaceutical
  • Published Report
  • Mar 2022
  • Europe
  • 350 Pages
  • No of Tables: 91
  • No of Figures: 43

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 DRUGS LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 EPIDEMIOLOGY

4.2 PESTEL

4.3 PORTER'S FIVE

4.4 PIPELINE ANALYSIS

5 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: REGULATIONS

5.1 REGULATION IN U.S.:

5.2 REGULATION IN EUROPE:

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISE IN INCIDENCE AND PREVALENCE OF AATD

6.1.2 WIDE RANGE OF RISKS AND COMORBIDITIES WITH AATD

6.1.3 IMPROVING DIAGNOSTIC TECHNIQUES FOR GENETIC DISORDERS

6.1.4 IMPROVED TECHNOLOGY FOR PRODUCTION AND PURIFICATION METHODS OF AAT

6.2 RESTRAINTS

6.2.1 HIGH COST OF THERAPIES

6.2.2 SIDE EFFECTS AND COMPLICATIONS OF AUGMENTATION THERAPIES

6.3 OPPORTUNITIES

6.3.1 GROWING R & D ACTIVITIES

6.3.2 STRATEGIC INITIATIVES BY KEY PLAYERS

6.3.3 RISE IN HEALTHCARE EXPENDITURE

6.4 CHALLENGES

6.4.1 DIFFICULTY IN SPECIFIC IDENTIFICATION OF AATD

6.4.2 STRINGENT RULES AND REGULATIONS

7 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS

7.1 OVERVIEW

7.2 PROLASTIN

7.3 ZEMAIRA/RESPREEZA

7.4 GLASSIA

7.5 ARALAST NP

7.6 OTHERS

8 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE

8.1 OVERVIEW

8.2 TYPE ‘PIZZ’

8.3 TYPE ‘PIMS’

8.4 TYPE ‘PIMZ’

8.5 OTHERS

9 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 LUNG DISEASE

9.2.1 EMPHYSEMA

9.2.2 COPD

9.2.3 LUNG CANCER

9.3 LIVER DISEASE

9.3.1 CIRRHOSIS

9.3.2 HEPATITIS

9.3.3 LIVER FAILURE

10 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE

10.1 OVERVIEW

10.2 ADULTS

10.3 PEDIATRIC

11 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 SPECIALTY CLINICS

11.4 HOME HEALTHCARE

11.5 OTHERS

12 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 HOSPITAL PHARMACY

12.3 RETAIL PHARMACY

12.4 ONLINE PHARMACY

12.5 OTHERS

13 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY REGION

13.1 EUROPE

13.1.1 GERMANY

13.1.2 U.K.

13.1.3 FRANCE

13.1.4 ITALY

13.1.5 SPAIN

13.1.6 NETHERLANDS

13.1.7 SWITZERLAND

13.1.8 RUSSIA

13.1.9 TURKEY

13.1.10 REST OF EUROPE

14 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: EUROPE

15 SWOT ANALYSIS

16 COMPANY PROFILE

16.1 GRIFOLS, S.A.

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 PRODUCT PORTFOLIO

16.1.4 RECENT DEVELOPMENTS

16.2 CSL

16.2.1 COMPANY SNAPSHOT

16.2.2 PRODUCT PORTFOLIO

16.2.3 RECENT DEVELOPMENT

16.3 TAKEDA PHARMACEUTICAL COMPANY LIMITED

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 PRODUCT PORTFOLIO

16.3.4 RECENT DEVELOPMENT

16.4 KAMADA PHARMACEUTICALS

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 PRODUCT PORTFOLIO

16.4.4 RECENT DEVELOPMENT

16.5 LFB BIOMEDICAMENTS

16.5.1 COMPANY SNAPSHOT

16.5.2 PRODUCT PORTFOLIO

16.5.3 RECENT DEVELOPMENT

16.6 APIC BIO

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT DEVELOPMENT

16.7 ARROWHEAD PHARMACEUTICALS, INC.

16.7.1 COMPANY SNAPSHOT

16.7.2 PRODUCT PORTFOLIO

16.7.3 RECENT DEVELOPMENT

16.8 BEAM THERAPEUTICS

16.8.1 COMPANY SNAPSHOT

16.8.2 PRODUCT PORTFOLIO

16.8.3 RECENT DEVELOPMENT

16.9 CENTESSA PHARMACEUTICALS (Z FACTOR)

16.9.1 COMPANY SNAPSHOT

16.9.2 PRODUCT PORTFOLIO

16.9.3 RECENT DEVELOPMENTS

16.1 INHIBRX, INC.

16.10.1 COMPANY SNAPSHOT

16.10.2 PRODUCT PORTFOLIO

16.10.3 RECENT DEVELOPMENT

16.11 INTELLIA THERAPEUTICS, INC.

16.11.1 COMPANY SNAPSHOT

16.11.2 PRODUCT PORTFOLIO

16.11.3 RECENT DEVELOPMENT

16.12 KRYSTAL BIOTECH

16.12.1 COMPANY SNAPSHOT

16.12.2 PRODUCT PORTFOLIO

16.12.3 RECENT DEVELOPMENT

16.13 LOGICBIO THERAPEUTICS, INC.

16.13.1 COMPANY SNAPSHOT

16.13.2 PRODUCT PORTFOLIO

16.13.3 RECENT DEVELOPMENT

16.14 MEREO BIOPHARMA GROUP PLC

16.14.1 COMPANY SNAPSHOT

16.14.2 PRODUCT PORTFOLIO

16.14.3 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

List of Table

TABLE 1 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, PIPELINE ANALYSIS

TABLE 2 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 3 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)

TABLE 4 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 5 U.S. LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 6 U.S. LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 7 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 8 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 9 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 10 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 11 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 12 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)

TABLE 13 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 14 EUROPE LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 15 EUROPE LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 16 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 17 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 18 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 19 GERMANY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 20 GERMANY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)

TABLE 21 GERMANY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 22 GERMANY LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 23 GERMANY LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 24 GERMANY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 25 GERMANY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 26 GERMANY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 27 U.K. ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 28 U.K. ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)

TABLE 29 U.K. ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 30 U.K. LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 31 U.K. LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 32 U.K. ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 33 U.K. ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 34 U.K. ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 35 FRANCE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 36 FRANCE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)

TABLE 37 FRANCE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 38 FRANCE LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 39 FRANCE LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 40 FRANCE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 41 FRANCE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 42 FRANCE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 43 ITALY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 44 ITALY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)

TABLE 45 ITALY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 46 ITALY LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 47 ITALY LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 48 ITALY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 49 ITALY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 50 ITALY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 51 SPAIN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 52 SPAIN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)

TABLE 53 SPAIN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 54 SPAIN LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 55 SPAIN LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 56 SPAIN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 57 SPAIN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 58 SPAIN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 59 NETHERLANDS ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 60 NETHERLANDS ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)

TABLE 61 NETHERLANDS ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 62 NETHERLANDS LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 63 NETHERLANDS LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 64 NETHERLANDS ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 65 NETHERLANDS ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 66 NETHERLANDS ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 67 SWITZERLAND ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 68 SWITZERLAND ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)

TABLE 69 SWITZERLAND ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 70 SWITZERLAND LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 71 SWITZERLAND LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 72 SWITZERLAND ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 73 SWITZERLAND ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 74 SWITZERLAND ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 75 RUSSIA ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 76 RUSSIA ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)

TABLE 77 RUSSIA ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 78 RUSSIA LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 79 RUSSIA LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 80 RUSSIA ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 81 RUSSIA ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 82 RUSSIA ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 83 TURKEY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 84 TURKEY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)

TABLE 85 TURKEY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 86 TURKEY LUNG DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 87 TURKEY LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 88 TURKEY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 89 TURKEY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 90 TURKEY ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 91 REST OF EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET, BY DRUGS, 2020-2029 (USD MILLION)

List of Figure

FIGURE 1 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: SEGMENTATION

FIGURE 2 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: DROC ANALYSIS

FIGURE 4 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS

FIGURE 5 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: SEGMENTATION

FIGURE 11 RISING PREVALENCE AND AWARENESS OF AATD IS EXPECTED TO DRIVE THE EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 PROLASTIN SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET

FIGURE 14 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY DRUGS, 2021

FIGURE 15 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY DRUGS, 2022-2029 (USD MILLION)

FIGURE 16 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY DRUGS, CAGR (2022-2029)

FIGURE 17 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY DRUGS, LIFELINE CURVE

FIGURE 18 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY GENE TYPE, 2021

FIGURE 19 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY GENE TYPE, 2022-2029 (USD MILLION)

FIGURE 20 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY GENE TYPE, CAGR (2022-2029)

FIGURE 21 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY GENE TYPE, LIFELINE CURVE

FIGURE 22 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY APPLICATION, 2021

FIGURE 23 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY APPLICATION, 2022-2029 (USD MILLION)

FIGURE 24 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY APPLICATION, CAGR (2022-2029)

FIGURE 25 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 26 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY POPULATION TYPE, 2021

FIGURE 27 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY AGE GROUP, 2022-2029 (USD MILLION)

FIGURE 28 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY POPULATION TYPE, CAGR (2022-2029)

FIGURE 29 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY POPULATION TYPE, LIFELINE CURVE

FIGURE 30 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY END USER, 2021

FIGURE 31 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 32 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY END USER, CAGR (2022-2029)

FIGURE 33 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY END USER, LIFELINE CURVE

FIGURE 34 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 35 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 36 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 37 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: SNAPSHOT (2021)

FIGURE 39 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY COUNTRY (2021)

FIGURE 40 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY COUNTRY (2022 & 2029)

FIGURE 41 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY COUNTRY (2021 & 2029)

FIGURE 42 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: BY DRUGS (2022-2029)

FIGURE 43 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AUGMENTATION THERAPY MARKET: COMPANY SHARE 2021 (%)